These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12756895)

  • 1. [Approximation to the cost of pharmacological treatment of rheumatoid arthritis in Spain].
    Mera Varela A; Blanco Rodríguez J; Caamaño Freire M
    An Med Interna; 2003 Mar; 20(3):114-21. PubMed ID: 12756895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic burden of illness imposed by severe sepsis in Austria.
    Schmid A; Schneider H; Adlof A; Smolle KH; Edelmann G; Sporn P; Frass M; Sumann G; Koller W; Schobersberger W
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):697-701. PubMed ID: 12602114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
    Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
    Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).
    Hallert E; Husberg M; Skogh T
    Rheumatology (Oxford); 2006 Mar; 45(3):325-31. PubMed ID: 16287927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists?
    Gabriel SE; Wagner JL; Zinsmeister AR; Scott CG; Luthra HS
    Arthritis Rheum; 2001 Jul; 44(7):1504-14. PubMed ID: 11465700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
    Capell H; McCarey D; Madhok R; Hampson R
    J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Maetzel A; Strand V; Tugwell P; Wells G; Bombardier C
    Arthritis Rheum; 2002 Dec; 47(6):655-61. PubMed ID: 12522841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
    Michaud K; Messer J; Choi HK; Wolfe F
    Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
    Merkesdal S; Ruof J
    Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.
    Yazdani C; McLaughlin T; Cummins G; Doyle J
    Am J Manag Care; 2001 Sep; 7(13 Suppl):S419-26. PubMed ID: 11594238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
    Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
    Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
    Blanco FJ; Ballina J; Carbonell J; Martín-Mola E; Tornero J; Ramírez E; Galván J
    Reumatol Clin; 2011; 7(2):88-93. PubMed ID: 21794790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
    McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
    J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
    Kvamme MK; Lie E; Kvien TK; Kristiansen IS
    Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect cost assessment in patients with rheumatoid arthritis (RA): comparison of data from the health economic patient questionnaire HEQ-RA and insurance claims data.
    Merkesdal S; Ruof J; Huelsemann JL; Mittendorf T; Handelmann S; Mau W; Zeidler H
    Arthritis Rheum; 2005 Apr; 53(2):234-40. PubMed ID: 15818718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
    J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T; Pincus T
    J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.